Xu Jin

Research Areas : Neoadjuvant conversion therapy for pancreatic cancer, peritoneal metastasis of pancreatic cancer; Cutting-edge Technology: Neoadjuvant therapy for pancreatic cancer + HIPEC (hyperthermic intraperitoneal perfusion) combined regimen; Areas of Expertise: Locally advanced pancreatic cancer, peritoneal metastasis of pancreatic cancer, periampullary cancer; Academic Highlights: Key expert in pancreatic cancer conversion therapy; Core Value: Improved screening criteria for conversion surgery in locally advanced pancreatic cancer, increasing the surgical conversion rate of unresectable pancreatic cancer.